Advertisement
Home »

Detection of TP53 mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status.

May 26, 2025

ABOUT THE EXPERTS

  • Lee P Richman

    Department of Pathology, Brigham and Women’s Hospital, Boston, MA, United States.

    Brianna F Waller

    Department of Pathology, Brigham and Women’s Hospital, Boston, MA, United States.

    Scott B Lovitch

    Department of Pathology, Brigham and Women’s Hospital, Boston, MA, United States.

    Ashwini Jambhekar

    Department of Systems Biology, Harvard Medical School, Boston, MA, United States.

    Ludwig Center at Harvard, Boston, MA, United States.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement